Prelude Therapeutics Inc

For the period ended Jun 30, 2026. Filed Aug 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 11, 2026

PRLD$3.76+4.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Changes in Stockholders’ Equity (Unaudited)

STATEMENTS OF CHANGES INSTOCKHOLDERS’ EQUITY

Voting common stock · Non-voting commonstock · Additional paid-in · Accumulated other comprehensive · Accumulated
(in thousands, except shares) · Shares · Amount · Shares · Amount · capital · income (loss) · deficit · Total
Balance at January 1, 2026	48,225,493	$5	14,728,135	$1	$751,684		$8		$(683,061)		$68,637
Issuance of common stock upon vesting of RSUs, net of 21,426 shares withheld for employee taxes	64,594	—	—	—	(20)		—		—		(20)
Unrealized loss on marketable securities, net of tax	—	—	—	—		(49)		—		(49)
Stock-based compensation expense	—	—	—	—	2,000		—		—		2,000
Net loss	—	—	—	—		—		(10,385)		(10,385)
Balance at March 31, 2026	48,290,087	$5	14,728,135	$1	$753,664		$(41)		$(693,446)		$60,183
Issuance of common stock and prefunded warrants, net of issuance costs of $4,556.5 thousand	16,611,014	2	—	—	85,441		—		—		85,443
Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 3,861 shares withheld for employee taxes	78,119	—	—	—	72		—		—		72
Issuance of common stock upon under ESPP	49,776	—	—	—	115		—		—		115
Unrealized loss on marketable securities, net of tax	—	—	—	—	—		(186)		—		(186)
Stock-based compensation expense	—	—	—	—	2,027		—		—		2,027
Net loss	—	—	—	—	—		—		(13,921)		(13,921)
Balance at June 30, 2026	65,028,996	$7	14,728,135	$1	$841,319		$(227)		$(707,367)		$133,733

STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (CONTINUED)

Voting common stock · Non-voting common stock · Additional paid-in · Accumulated other comprehensive · Accumulated
(in thousands, except shares) · Shares · Amount · Shares · Amount · capital · income (loss) · deficit · Total
Balance at January 1, 2025	42,298,859	$4	12,850,259	$1	$714,982		$35		$(583,563)		$131,459
Issuance of common stock upon vesting of RSUs, net of 3,859 shares withheld for employee taxes	5,516	—	—	—	(5)		—		—		(5)
Issuance of common stock upon exercise of prefunded warrants	1,299,827	—	—	—	—		—		—		—
Unrealized loss on marketable securities, net of tax	—	—	—	—	—		(23)		—		(23)
Stock-based compensation expense	—	—	—	—	3,832		—		—		3,832
Net loss	—	—	—	—	—		—		(32,085)		(32,085)
Balance at March 31, 2025	43,604,202	$4	12,850,259	$1	$718,809		$12		$(615,648)		$103,178
Issuance of common stock upon exercise of stock options & vesting of RSUs, net of 3,355 shares withheld for employee taxes	6,020	—	—	—	(2)		—		—		(2)
Issuance of common stock under ESPP	133,844	—	—	—	92		—		—		92
Unrealized loss on marketable securities, net of tax	—	—	—	—	—		(13)		—		(13)
Stock-based compensation expense	—	—	—	—	3,814		—		—		3,814
Net loss	—	—	—	—		—		(31,231)		(31,231)
Balance at June 30, 2025	43,744,066	$4	12,850,259	$1	$722,713		$(1)		$(646,879)		$75,838

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.